CDMO Growth, Peptides & 30% Margins: Laurus Labs CEO Reveals Growth Plans
NDTV Profit · 01 Nov 2026 · 13 min
Management interview of Laurus Labs Ltd (LAURUSLABS), with 6 key numbers discussed.
- Satyanarayana Chava, Founder and CEO, Laurus Labs
Laurus Labs plans to maintain gross margins above 60% and EBITDA margins above 30% in the near to medium term. The company is actively investing in CDMO capacity across peptides, crop sciences, and animal health with strong customer visibility. Management expects CDMO revenues to contribute over 50% of total revenue by FY29, while meaningful crop science revenues are projected to materialize in FY29. Return on equity is expected to exceed 25% within 24 to 36 months, supported by stable capex and declining net debt to EBITDA.